Edition:
United Kingdom

Applied DNA Sciences Inc (APDN.OQ)

APDN.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
19 Aug 2019
Change (% chg)

$0.01 (+3.39%)
Prev Close
$0.28
Open
$0.30
Day's High
$0.30
Day's Low
$0.29
Volume
3,954
Avg. Vol
75,869
52-wk High
$1.82
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

Applied DNA And Theracann International Sign Term Sheet To Amend Licensing And Cooperation Agreement
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA AND THERACANN INTERNATIONAL SIGN TERM SHEET TO AMEND LICENSING AND COOPERATION AGREEMENT.APPLIED DNA SCIENCES INC - AMENDMENTS FORTIFY AGREEMENT, ALLOW REVENUE RECOGNITION, AND STRENGTHEN APPLIED DNA BALANCE SHEET.APPLIED DNA SCIENCES INC - APPLIED DNA NOTES THAT TERM SHEET IS A PRELIMINARY AND NON-BINDING DOCUMENT.APPLIED DNA SCIENCES INC - AGREED TO AMEND AGREEMENT TO PROVIDE CO WITH $4 MILLION IN THERACANN CONVERTIBLE PREFERRED STOCK.APPLIED DNA SCIENCES INC - AGREED TO AMEND AGREEMENT TO PROVIDE CO WITH $1 MILLION CONVERTIBLE PROMISSORY NOTE.APPLIED DNA - PREFERRED STOCK, PROMISSORY NOTE AMENDMENTS IN EXCHANGE FOR CO'S WAIVER OF $4 MILLION IN PAYMENTS DUE FROM THERACANN ON/BEFORE AUG 15.  Full Article

Applied DNA Sciences Says Entered Into Agreement With Unit Of Theracann
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES SAYS ON MARCH 28, CO, UNIT ENTERED INTO PATENT & KNOW-HOW LICENSE & COOPERATION AGREEMENT WITH A UNIT OF THERACANN - SEC FILING.APPLIED DNA SCIENCES - UNDER AGREEMENT, A $5 MILLION NON-REFUNDABLE UP-FRONT LICENSING FEE IS PAYABLE TO CO AND ITS UNIT OVER A FOUR-MONTH PERIOD.  Full Article

Applied DNA Reports Q1 Loss Per Share Of $0.11
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE ROSE 37 PERCENT TO $884,000.  Full Article

Applied Dna Announces Pricing Of $2.75 Million Offering Of Common Stock And Warrants
Friday, 21 Dec 2018 

Applied DNA Sciences Inc ::APPLIED DNA ANNOUNCES PRICING OF $2.75 MILLION OFFERING OF COMMON STOCK AND WARRANTS.APPLIED DNA SCIENCES INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS.APPLIED DNA SCIENCES INC - PRICING OF 5.5 MILLION COMMON SHARES AND WARRANTS TO BUY UP TO 5.5 MILLION SHARES OF COMPANY'S COMMON STOCK.APPLIED DNA SCIENCES INC - COMBINED OFFERING PRICE OF $0.50 PER SHARE.  Full Article

Applied DNA Sciences Q4 Loss Per Share $0.12
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA ANNOUNCES SELECTED PRELIMINARY UNAUDITED FISCAL 2018 YEAR END AND FOURTH QUARTER FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.12.Q4 REVENUE $1.2 MILLION.  Full Article

Applied DNA Sciences Shipped Over 8,000 Milligrams Of PCR-Produced Linear DNA In 12 Months
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES REACHES NEW MILESTONES IN THERAPEUTIC CONTRACT RESEARCH AND CONTRACT MANUFACTURING OF LINEAR DNA.APPLIED DNA SCIENCES - IN PAST 12 MONTHS, SHIPPED OVER 8,000 MILLIGRAMS OF PCR-PRODUCED LINEAR DNA.  Full Article

Wuhan Thalys Medical Technology and partner jointly sign contract with Pingdu People's Hospital
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it and China Resources Shandong Pharmaceutical Co Ltd jointly signed contract with Pingdu People's Hospital, regarding centralized purchasing and supply of test reagent and consumable.  Full Article

Wuhan Thalys Medical Technology signs contracts with Wuhan Hospital of Traditional Chinese Medicine
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it signed contracts with Wuhan Hospital of Traditional Chinese Medicine, regarding centralized delivery of test reagent and consumable.  Full Article

Applied DNA Sciences Q4 Revenue $1.1 Million
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA SCIENCES REPORTS YEAR END AND FISCAL FOURTH QUARTER RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE FELL 30 PERCENT TO $1.1 MILLION.  Full Article

Wuhan Thalys Medical Technology unit sets up medical tech unit in Tai'an City
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says co's Jinan-based medical technology unit sets up a wholly owned medical technology unit in Tai'an City, with registered capital of 10 million yuan .  Full Article

BRIEF-Applied DNA Sciences Signs A 5-Year Pact With Montblanc-Simplo GMBH

* APPLIED DNA SIGNS 5-YEAR AGREEMENT WITH ICONIC WRITING INSTRUMENT SPECIALIST MONTBLANC-SIMPLO GMBH TO PROVIDE SIGNATURE® DNA WITH BEACON® TO PRESTIGE MONTBLANC CLIENTS